NCT03962543 2026-04-08ReNeuSpringWorks Therapeutics, Inc.Phase 2 Active not recruiting114 enrolled 25 charts 3 FDA
NCT06322342 2025-12-26Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast AgentReveal Pharmaceuticals Inc.Phase 2 Completed18 enrolled
NCT05891847 2025-06-10Non-interventional Study of Patients With PN NF1 Starting Selumetinib in RussiaAstraZenecaActive not recruiting150 enrolled